ZA200401803B - Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intra-myocellular lipid level. - Google Patents

Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intra-myocellular lipid level. Download PDF

Info

Publication number: ZA200401803B
Authority: ZA; South Africa
Prior art keywords: lipid; food product; fatty acids; lipid blend; family
Prior art date: 2001-08-08

Application number

ZA200401803A

Other languages

English (en)

Inventor

Jacques Decombaz

Catherine Mace

Original Assignee

Nestle Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-08

Filing date

2004-03-04

Publication date

2005-04-21

2004-03-04 Application filed by Nestle Sa filed Critical Nestle Sa

2005-04-21 Publication of ZA200401803B publication Critical patent/ZA200401803B/en

Links

150000002632 lipids Chemical class 0.000 title claims description 57
239000000203 mixture Substances 0.000 title claims description 49
235000013305 food Nutrition 0.000 title claims description 27
235000014113 dietary fatty acids Nutrition 0.000 title claims description 18
229930195729 fatty acid Natural products 0.000 title claims description 18
239000000194 fatty acid Substances 0.000 title claims description 18
-1 oleic fatty acid Chemical class 0.000 title 1
229940033080 omega-6 fatty acid Drugs 0.000 title 1
235000020665 omega-6 fatty acid Nutrition 0.000 title 1
150000004665 fatty acids Chemical class 0.000 claims description 17
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 10
235000013336 milk Nutrition 0.000 claims description 10
239000008267 milk Substances 0.000 claims description 10
210000004080 milk Anatomy 0.000 claims description 10
235000016709 nutrition Nutrition 0.000 claims description 10
238000000034 method Methods 0.000 claims description 9
230000001965 increasing effect Effects 0.000 claims description 8
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 8
235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 8
235000021314 Palmitic acid Nutrition 0.000 claims description 7
235000021355 Stearic acid Nutrition 0.000 claims description 7
150000001720 carbohydrates Chemical class 0.000 claims description 7
235000014633 carbohydrates Nutrition 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 5
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 5
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 5
239000005642 Oleic acid Substances 0.000 claims description 5
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 5
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 5
235000020778 linoleic acid Nutrition 0.000 claims description 5
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 5
150000002943 palmitic acids Chemical class 0.000 claims description 5
235000020661 alpha-linolenic acid Nutrition 0.000 claims description 4
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 4
235000013339 cereals Nutrition 0.000 claims description 4
235000015897 energy drink Nutrition 0.000 claims description 4
229960004488 linolenic acid Drugs 0.000 claims description 4
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 4
235000021056 liquid food Nutrition 0.000 claims description 4
230000035764 nutrition Effects 0.000 claims description 4
239000000843 powder Substances 0.000 claims description 4
235000013351 cheese Nutrition 0.000 claims description 3
235000015140 cultured milk Nutrition 0.000 claims description 3
235000015243 ice cream Nutrition 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
235000013618 yogurt Nutrition 0.000 claims description 3
150000001413 amino acids Chemical class 0.000 claims description 2
230000000290 insulinogenic effect Effects 0.000 claims description 2
102000004169 proteins and genes Human genes 0.000 claims description 2
108090000623 proteins and genes Proteins 0.000 claims description 2
239000000126 substance Substances 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 1
210000003205 muscle Anatomy 0.000 description 14
235000019197 fats Nutrition 0.000 description 11
229920002527 Glycogen Polymers 0.000 description 10
235000005911 diet Nutrition 0.000 description 10
229940096919 glycogen Drugs 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
210000000663 muscle cell Anatomy 0.000 description 9
238000009825 accumulation Methods 0.000 description 7
230000008901 benefit Effects 0.000 description 7
230000037213 diet Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
210000004027 cell Anatomy 0.000 description 5
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
206010022489 Insulin Resistance Diseases 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000000378 dietary effect Effects 0.000 description 4
239000008103 glucose Substances 0.000 description 4
229940049918 linoleate Drugs 0.000 description 4
239000002609 medium Substances 0.000 description 4
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
239000000047 product Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
125000005456 glyceride group Chemical group 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
150000004668 long chain fatty acids Chemical class 0.000 description 3
239000000463 material Substances 0.000 description 3
235000021313 oleic acid Nutrition 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
102000009024 Epidermal Growth Factor Human genes 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000008157 edible vegetable oil Substances 0.000 description 2
235000004626 essential fatty acids Nutrition 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000000446 fuel Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
238000011534 incubation Methods 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
239000011707 mineral Substances 0.000 description 2
235000021281 monounsaturated fatty acids Nutrition 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
229940049964 oleate Drugs 0.000 description 2
230000037081 physical activity Effects 0.000 description 2
230000036314 physical performance Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
235000003441 saturated fatty acids Nutrition 0.000 description 2
150000004671 saturated fatty acids Chemical class 0.000 description 2
230000000276 sedentary effect Effects 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
206010018429 Glucose tolerance impaired Diseases 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
208000029578 Muscle disease Diseases 0.000 description 1
235000021319 Palmitoleic acid Nutrition 0.000 description 1
108010009736 Protein Hydrolysates Proteins 0.000 description 1
FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
239000005862 Whey Substances 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000000386 athletic effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
235000020934 caloric restriction Nutrition 0.000 description 1
229960004203 carnitine Drugs 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
230000005465 channeling Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000008021 deposition Effects 0.000 description 1
235000021004 dietary regimen Nutrition 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
230000037149 energy metabolism Effects 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000011536 extraction buffer Substances 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000002828 fuel tank Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
235000009200 high fat diet Nutrition 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000013190 lipid storage Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
235000015263 low fat diet Nutrition 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
150000002680 magnesium Chemical class 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940057917 medium chain triglycerides Drugs 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000001964 muscle biopsy Methods 0.000 description 1
210000001256 muscle mitochondria Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
230000021268 myoblast fusion Effects 0.000 description 1
210000001087 myotubule Anatomy 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
150000002889 oleic acids Chemical class 0.000 description 1
239000003346 palm kernel oil Substances 0.000 description 1
235000019865 palm kernel oil Nutrition 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
235000014438 salad dressings Nutrition 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000007790 scraping Methods 0.000 description 1
230000028201 sequestering of triglyceride Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000002363 skeletal muscle cell Anatomy 0.000 description 1
210000001057 smooth muscle myoblast Anatomy 0.000 description 1
235000021055 solid food Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229940099373 sudan iii Drugs 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000012549 training Methods 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
229940117972 triolein Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Polymers & Plastics (AREA)
Engineering & Computer Science (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Zoology (AREA)
Nutrition Science (AREA)
Animal Husbandry (AREA)
Mycology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Birds (AREA)
Obesity (AREA)
Bioinformatics & Cheminformatics (AREA)
Pediatric Medicine (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Edible Oils And Fats (AREA)
Fats And Perfumes (AREA)
General Preparation And Processing Of Foods (AREA)
Fodder In General (AREA)
Confectionery (AREA)
Dairy Products (AREA)

ZA200401803A 2001-08-08 2004-03-04 Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intra-myocellular lipid level. ZA200401803B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP01119155A EP1285590A1 (de)	2001-08-08	2001-08-08	Lipidmischungen

Publications (1)

Publication Number	Publication Date
ZA200401803B true ZA200401803B (en)	2005-04-21

Family

ID=8178277

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200401803A ZA200401803B (en)	2001-08-08	2004-03-04	Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intra-myocellular lipid level.

Country Status (18)

Country	Link
US (1)	US20050042256A1 (de)
EP (2)	EP1285590A1 (de)
JP (1)	JP2004536619A (de)
KR (1)	KR20040019112A (de)
CN (1)	CN1319472C (de)
AT (1)	ATE354972T1 (de)
AU (1)	AU2002325344B2 (de)
BR (1)	BR0211771A (de)
CA (1)	CA2456159A1 (de)
CO (1)	CO5550401A2 (de)
DE (1)	DE60218481T2 (de)
IL (2)	IL159870A0 (de)
MX (1)	MXPA04001129A (de)
NO (1)	NO326413B1 (de)
PL (1)	PL368188A1 (de)
RU (1)	RU2297152C2 (de)
WO (1)	WO2003013276A1 (de)
ZA (1)	ZA200401803B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7223434B2 (en) *	2001-11-21	2007-05-29	Gerber Products Company	Blended baby foods
GB0311081D0 (en) *	2003-05-14	2003-06-18	Btg Internat Limted	Treatment of neurodegenerative conditions
GB2422373B (en)	2003-08-18	2008-05-21	Btg Int Ltd	Treatment of neurodegenerative conditions
GB0425932D0 (en) *	2004-11-25	2004-12-29	Btg Int Ltd	Structured phospholipids
GB0504362D0 (en) *	2005-03-02	2005-04-06	Btg Int Ltd	Cytokine modulators
GB0504333D0 (en) *	2005-03-02	2005-04-06	Btg Int Ltd	Treatment of cytokine dysregulation
US8110231B2 (en)	2006-04-10	2012-02-07	Kraft Foods Global Brands Llc	Methods for making improved texture cereal bars
WO2009002146A1 (en)	2007-06-26	2008-12-31	N.V. Nutricia	Supporting activities of daily living
WO2009002148A1 (en)	2007-06-27	2008-12-31	N.V. Nutricia	Food composition for prodromal dementia patients
MX2010000224A (es)	2007-06-26	2010-05-03	Nutricia Nv	Mejoramiento de la memoria en individuos con mini-examen de estado mental de 24-26.
WO2009002145A1 (en)	2007-06-26	2008-12-31	N.V. Nutricia	Lipid composition for improving function of brain functioning
MX2010006829A (es)	2007-12-20	2010-09-30	Nutricia Nv	Producto que contiene nucleotidos/nucleosidos liquidos.
US20090264520A1 (en) *	2008-04-21	2009-10-22	Asha Lipid Sciences, Inc.	Lipid-containing compositions and methods of use thereof
US20110098358A1 (en) *	2008-06-11	2011-04-28	Ricom Corporation	Human beta3 adrenergic receptor ligand, and food or pharmaceutical product containing the same
EP2251428B1 (de) *	2009-05-11	2011-10-19	Loders Croklaan B.V.	Verfahren zur Herstellung einer Triglyceridzusammensetzung
WO2017177133A1 (en) *	2016-04-09	2017-10-12	QalibreMD, Inc.	Novel compositions that mimic adipose tissue in mri
CN107254434B (zh) *	2017-06-14	2021-04-30	江苏省家禽科学研究所	油酸诱导鸡成肌细胞肌内脂肪沉积的应用及诱导方法
CN110833118A (zh) *	2018-08-15	2020-02-25	广西大学	一种促进肌内脂肪积累的饲料及提高小鼠肌内脂肪积累的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8813766D0 (en) *	1988-06-10	1988-07-13	Efamol Holdings	Essential fatty acid compositions
ES2138987T3 (es) *	1993-08-20	2000-02-01	Nestle Sa	Composicion lipidica para uso alimenticio.
PT893064E (pt) *	1997-07-22	2003-04-30	Nestle Sa	Composicao lipidica para formulacao infantil e processo de preparacao
US6228367B1 (en) *	1999-12-22	2001-05-08	Renew Life, Inc.	Food supplement formulation

2001
- 2001-08-08 EP EP01119155A patent/EP1285590A1/de not_active Withdrawn
2002
- 2002-07-10 AT AT02758363T patent/ATE354972T1/de not_active IP Right Cessation
- 2002-07-10 JP JP2003518302A patent/JP2004536619A/ja not_active Withdrawn
- 2002-07-10 EP EP02758363A patent/EP1416812B1/de not_active Expired - Lifetime
- 2002-07-10 BR BR0211771-1A patent/BR0211771A/pt not_active IP Right Cessation
- 2002-07-10 KR KR10-2004-7001732A patent/KR20040019112A/ko not_active Ceased
- 2002-07-10 IL IL15987002A patent/IL159870A0/xx active IP Right Grant
- 2002-07-10 AU AU2002325344A patent/AU2002325344B2/en not_active Ceased
- 2002-07-10 CA CA002456159A patent/CA2456159A1/en not_active Abandoned
- 2002-07-10 WO PCT/EP2002/008051 patent/WO2003013276A1/en not_active Ceased
- 2002-07-10 MX MXPA04001129A patent/MXPA04001129A/es active IP Right Grant
- 2002-07-10 RU RU2004106606/13A patent/RU2297152C2/ru not_active IP Right Cessation
- 2002-07-10 PL PL02368188A patent/PL368188A1/xx not_active IP Right Cessation
- 2002-07-10 DE DE60218481T patent/DE60218481T2/de not_active Expired - Fee Related
- 2002-07-10 US US10/485,582 patent/US20050042256A1/en not_active Abandoned
- 2002-07-10 CN CNB028155009A patent/CN1319472C/zh not_active Expired - Fee Related
2004
- 2004-01-14 IL IL159870A patent/IL159870A/en not_active IP Right Cessation
- 2004-01-29 NO NO20040684A patent/NO326413B1/no not_active IP Right Cessation
- 2004-02-06 CO CO04009618A patent/CO5550401A2/es not_active Application Discontinuation
- 2004-03-04 ZA ZA200401803A patent/ZA200401803B/en unknown

Also Published As

Publication number	Publication date
CA2456159A1 (en)	2003-02-20
DE60218481D1 (de)	2007-04-12
US20050042256A1 (en)	2005-02-24
AU2002325344B2 (en)	2007-12-13
EP1416812A1 (de)	2004-05-12
BR0211771A (pt)	2004-07-27
ATE354972T1 (de)	2006-03-15
IL159870A (en)	2006-08-20
RU2297152C2 (ru)	2007-04-20
CO5550401A2 (es)	2005-08-31
KR20040019112A (ko)	2004-03-04
RU2004106606A (ru)	2005-07-10
EP1285590A1 (de)	2003-02-26
JP2004536619A (ja)	2004-12-09
CN1538811A (zh)	2004-10-20
DE60218481T2 (de)	2007-11-15
NO326413B1 (no)	2008-12-01
CN1319472C (zh)	2007-06-06
IL159870A0 (en)	2004-06-20
NO20040684L (no)	2004-01-29
WO2003013276A1 (en)	2003-02-20
MXPA04001129A (es)	2004-05-20
EP1416812B1 (de)	2007-02-28
PL368188A1 (en)	2005-03-21

Publication	Publication Date	Title
EP1416812B1 (de)	2007-02-28	Lipid mischungen und lebensmittel, enthaltend ölsäure und omega-6 fettsäuren, die die intramyozelluläre lipidkonzentration erhöhen
Koletzko et al.	2001	Physiological aspects of human milk lipids
Calder et al.	2002	Polyunsaturated fatty acids, inflammation and immunity
AU2002325344A1 (en)	2003-06-19	Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lilpid level
Gaíva et al.	2003	Diets rich in polyunsaturated fatty acids: effect on hepatic metabolism in rats
MX2014005628A (es)	2014-10-17	Formula para lactantes con alto palmitato sn-2 y oligofructosa.
Nudda et al.	2008	Relationships between the contents of vaccenic acid, CLA and n− 3 fatty acids of goat milk and the muscle of their suckling kids
WO2013036104A1 (en)	2013-03-14	Infant nutrition for regulating food intake later in life
JP6387371B2 (ja)	2018-09-05	メタボリックシンドローム改善剤
CN112772924A (zh)	2021-05-11	一种功能食品专用油脂基料油及其制备方法和应用
Gurr	2018	Lipids and nutrition
Kennedy et al.	2005	Influence of dietary conjugated linoleic acid (CLA) on lipid and fatty acid composition in liver and flesh of Atlantic salmon (Salmo salar)
Akoh	2019	Structured and specialty lipids
SG172774A1 (en)	2011-08-29	Nutritional composition for infants
Li	2022	Overview of dietary lipids and human health
O’Shea et al.	2019	CLA sources and human studies
JPH10262607A (ja)	1998-10-06	乳幼児用栄養組成物
Ling et al.	2012	Arachidonic acid and docosahexaenoic acid supplemented to an essential fatty acid–deficient diet alters the response to endotoxin in rats
US20090298937A1 (en)	2009-12-03	Method for Inhibiting the Growth of Bacteria
Huth et al.	2010	Bioactivity and emerging role of short and medium chain fatty acids
Naveen et al.	2021	Metabolomics of dietary fatty acids: Implications on life style diseases
Tashiro et al.	1998	Effects of a newly developed fat emulsion containing eicosapentaenoic acid and docosahexaenoic acid on fatty acid profiles in rats
Ling et al.	2010	Early development of essential fatty acid deficiency in rats: fat-free vs. hydrogenated coconut oil diet
Hunter et al.	1985	Isomeric fatty acids and tumorigenesis: a commentary on recent work
Berra	1993	Trans fatty acids in infantile nutrition